BioLineRx Announces Investigator-Initiated Study for Novel Chronic Myeloid ... MarketWatch Pre-clinical studies show that BL-8040 is efficient, both alone and in combination with anti-cancer drugs such as Rituximab, Imatinib and Bortezomib in lymphoma, CML and multiple myeloma models (respectively). BL-8040 also mobilizes stem cells from the ... |
